Dompé Farmaceutici
   HOME

TheInfoList



OR:

Dompé Farmaceutici is a
privately held A privately held company (or simply a private company) is a company whose Stock, shares and related rights or obligations are not offered for public subscription or publicly negotiated in their respective listed markets. Instead, the Private equi ...
pharmaceutical company based in
Milan Milan ( , , ; ) is a city in northern Italy, regional capital of Lombardy, the largest city in Italy by urban area and the List of cities in Italy, second-most-populous city proper in Italy after Rome. The city proper has a population of nea ...
. Founded as a
compounding pharmacy In the field of pharmacy, compounding (performed in compounding pharmacies) is preparation of custom medications to fit unique needs of patients that cannot be met with mass-produced formulations. This may be done, for example, to provide medic ...
in 1890 by Piedmontese Onorato Dompé, the company has grown to a global pharmaceutical company with around 900 employees. His son, Sergio Dompe is the current CEO. In 2012, Dompé acquired the eye health-focused Italian pharmaceutical company Anabasis Srl; they went on to develop the Anabasis product
cenegermin Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor. Cenegermin is a peripherally selective agonist An agonist is a chemical that activates ...
, an
eye drop Eye drops or eyedrops are liquid drops applied directly to the surface of the eye usually in small amounts such as a single drop or a few drops. Eye drops usually contain saline to match the salinity of the eye. Drops containing only saline ...
containing recombinant human
nerve growth factor Nerve growth factor (NGF) is a neurotrophic factor and neuropeptide primarily involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It is perhaps the prototypical growth factor, in that it was ...
, as a treatment for neurotrophic keratitis. Cenegermin was approved by the
FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...
in August 2018 as the first available treatment for neurotrophic keratitis, and received
orphan drug An orphan drug is a medication, pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by th ...
designation. Cenegermin is marketed under the name Oxervate. In the same year, the company announced plans to list shares as part of its move to focus on biotechnology and the treatment of specific diseases.


References

{{Reflist Pharmaceutical companies of Italy companies based in Milan